Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of MK-7262 with or without enlicitide in adults with elevated lipoprotein(a)
NL-OMON61490Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2026
- Modality
- Small Molecules, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of gefapixant and enlicitide in lipoprotein(a) hyperlipoproteinemia (Lp(a)) and hyperlipidemia (10 arms), sponsored by Merck & Co. Primary endpoints: Percent Change from Baseline in Lipoprotein(a) at Week 8, Percent Change from Baseline in LDL-C at Week 8 and 2 more. Started Sep 2026; status: recruiting.
02
Drugs
gefapixantenlicitide
03
Conditions
lipoprotein(a) hyperlipoproteinemia (Lp(a))hyperlipidemia
Beyond the preview
Go deeper on NL-OMON61490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61490.